|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Convertible notes payable and accrued interest, net of debt discounts – related party (Note 3) | ||||||||||||||||||||
| Derivative liabilities (Note 5) | ||||||||||||||||||||
| Borrowing and accrued interest under convertible lines of credit, net of debt discount – related party (Note 9) | ||||||||||||||||||||
| Borrowing and accrued interest under convertible line of credit, net of debt discount – related party (Note 9) | ||||||||||||||||||||
| Accrued dividends payable | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible notes payable and accrued interest, net of debt discounts – related party (Note 3) | ||||||||||||||||||||
| Derivative liabilities (Note 5) | ||||||||||||||||||||
| Borrowing and accrued interest under convertible line of credit, net of debt discount – related party (Note 9) | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at June 30, 2026 and December 31, 2025, redemption value: $7,966,000, liquidation value: $1,760,000 at June 30, 2026 | ||||||||||||||||||||
| Undesignated stock, $0.01 par value; 20,000,000 shares authorized at June 30, 2026 and December 31, 2025 20,000,000 shares designated at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,185,000 and 1,210,000 issued and outstanding at June 30, 2026 and December 31, 2025, respectively, liquidation value $1,185,000 at June 30, 2026 | ||||||||||||||||||||
| Common stock, $0.001 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, 66,311,910 and 65,201,995 issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ deficit |
Loading...
